NCT05437315

GD2/PSMA Bi-specific CAR-T Cells For the Treatment of GD2 and PSMA Positive Solid Tumors

Study Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/PSMA bi-specific CAR-T cell therapy in patients with GD2 and PSMA positive tumor. Another goal of the study is to learn more about the function of the anti-GD2/PSMA bi-specific CAR-T cells and their persistency in patients.

Want to learn more about this trial?

Request More Info

Interventions

bi-4SCAR GD2/PSMA T cellsBIOLOGICAL
Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV

Study Locations

FacilityCityStateCountry
Shenzhen Geno-immune Medical InstituteShenzhenGuangdongChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026